newsfilter
← Latest News
ClinicalTrials.gov·

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer - NCT04720664

Objective Response Rate (ORR), Duration of Response (DOR), Progression Free Survival (PFS), (and 2 more...)